Rabeprazole
- Generic Name
- Rabeprazole
- Brand Names
- Aciphex, Pariet
- Drug Type
- Small Molecule
- Chemical Formula
- C18H21N3O3S
- CAS Number
- 117976-89-3
- Unique Ingredient Identifier
- 32828355LL
- Background
Rabeprazole is an antiulcer drug in the class of proton pump inhibitors. It is a prodrug - in the acid environment of the parietal cells it turns into active sulphenamide form. Rabeprazole inhibits the H+, K+ATPase of the coating gastric cells and dose-dependent oppresses basal and stimulated gastric acid secretion.
- Indication
For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori eradication, and prevention of gastroinetestinal bleeds with NSAID use.
- Associated Conditions
- Duodenal Ulcer, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Heartburn, Helicobacter Pylori Infection, Non-erosive Reflux Esophagitis Disease (NERD), Vomiting, Zollinger-Ellison Syndrome, Develop NSAID-induced gastric ulcers, Erosive reflux esophagitis
- Associated Therapies
- -
A Study to Investigate the Effects of Gastric Acid Suppression by Rabeprazole and BMS-986165 on How Fast and Complete The Drug is Absorbed Into the Body of Healthy Participants
- First Posted Date
- 2019-06-07
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 21
- Registration Number
- NCT03979248
- Locations
- 🇳🇱
PRA Health Sciences - Netherlands, Groningen, Netherlands
Daily Four Times or Two Times Usage of PPI and Amoxicillin for the First or Second Line H. Pylori Eradication
- Conditions
- Interventions
- First Posted Date
- 2019-01-14
- Last Posted Date
- 2019-01-14
- Lead Sponsor
- Chang Gung Memorial Hospital
- Target Recruit Count
- 530
- Registration Number
- NCT03802318
- Locations
- 🇨🇳
Chang-Gung memorial hospital at Keelung, Keelung, Taiwan
Study to Evaluate the Effect of Rabeprazole on the Pharmacokinetics of Vadadustat
- Conditions
- Interventions
- First Posted Date
- 2018-12-28
- Last Posted Date
- 2019-03-22
- Lead Sponsor
- Akebia Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT03789032
- Locations
- 🇨🇦
inVentiv Health Clinique Inc., Québec City, Quebec, Canada
Drug-drug Interaction Between Belumosudil, Itraconazole, Rifampicin, Rabeprazole, and Omeprazole in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2018-05-21
- Last Posted Date
- 2022-05-25
- Lead Sponsor
- Kadmon Corporation, LLC
- Target Recruit Count
- 73
- Registration Number
- NCT03530995
- Locations
- 🇬🇧
Quotient Sciences Ltd, Ruddington, Nottingham, United Kingdom
Study to Determine the Single and Repeat Dose Pharmacokinetics, Food Effect, Proton Pump Inhibitor (PPI) Drug Interaction, Safety and Tolerability of Oral Prototype Formulations of BOS172767 in Healthy Subjects
- First Posted Date
- 2018-03-13
- Last Posted Date
- 2020-11-18
- Lead Sponsor
- Boston Pharmaceuticals
- Target Recruit Count
- 28
- Registration Number
- NCT03464058
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom
Efficacy and Safety of Hou Gu Mi Xi in Patients With Peptic Ulcer Diseases
- Conditions
- Interventions
- First Posted Date
- 2017-10-25
- Last Posted Date
- 2024-07-03
- Target Recruit Count
- 360
- Registration Number
- NCT03320538
- Locations
- 🇨🇳
Jiangxi University of Traditional Chinese Medicine, Nanchang, Jiangxi, China
A Study to Investigate the Effect of Formulation, Food, and Rabeprazole on the Pharmacokinetics (PK) of GDC-0853 in Healthy Participants
- First Posted Date
- 2017-09-25
- Last Posted Date
- 2019-09-11
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT03290703
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Bioavailability of GDC-0134 and the Effect of Food and Proton Pump Inhibitor on Pharmacokinetics of GDC-0134 in Healthy Female Participants
- Conditions
- Interventions
- First Posted Date
- 2017-08-02
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT03237741
- Locations
- 🇬🇧
Quotient Clinical Ltd, Clinical Research Unit, Nottingham, United Kingdom
Proton Pump Inhibitor (PPI, Rabeprazole) Effect On Tablet Formulation Of Palbociclib
- First Posted Date
- 2017-07-18
- Last Posted Date
- 2017-10-10
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03220191
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Study Of Glasdegib In Healthy Volunteers To Establish The Bioequivalence Of The Phase 2 Formulation To The ICH Formulation
- Conditions
- Interventions
- First Posted Date
- 2017-04-26
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT03130556
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.